Market research
ALTER.PA Theradiag SA
PA EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 17M
- P/E ratio
- 42.0
- Analyst target
- 3.8
- Dividend yield
- Not available
- Beta
- -0.27
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- FR0004197747
- Market cap
- 17M
- P/E ratio
- 42.0
- Analyst target
- 3.8
- Dividend yield
- Not available
- Beta
- -0.27
About
About Theradiag SA
Theradiag SA develops, manufactures, and markets in-vitro diagnostic products in France and internationally. The company offers LISA tracker, a tool for the monitoring of biotherapies; i-Tracker, a random access solution for therapeutic drug monitoring of biologics; i-Track10 for measurement of drug level and anti-drug antibodies; ez-Track 1 and ez-Tracker, a true point-of-care solution for therapeutic drug monitoring of biologics; and Immunotrol Tracker, a ready-to-use internal quality control sera for pharmacological dosage of biotherapies. It also provides autoimmune reagents for connective tissue diseases, rheumatoid arthritis, autoimmune liver diseases, vasculitis, celiac disease, anti-phospholipids syndrome, autoimmune thryroiditis, pernicious anemia, and other autoimmune diseases; IMMUNO-TROL, a multi-parametric precision control in autoimmunity; SQA-V system, a semen analyzer; V-Sperm for loading results, pictures, and videos of the samples into the computer; and rapid tests for colorectal cancer. In addition, the company offers instrumentation, including FIDIS system for simultaneous and specific detection of multiple analytes from the same sample in a single assay; and Theralis that integrates multiplex FIDIS immunofluorescence and ELISA. Theradiag SA was incorporated in 1986 and is based in Marne-la-Vallée, France. Theradiag SA operates as a subsidiary of Biosynex SA.
Research context
Theradiag SA appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ALTER.PA discussion.
5 years, 6 months ago
Theradiag SA is currently in a long term downtrend where the price is trading 26.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.2.
Finally, its free cash flow fell by 0.0% to $-426K since the same quarter in the previous year.
Based on the above factors, Theradiag SA gets an overall score of 1/5.